Similar Search Results

Cost Effectiveness of Fluvoxamine in the Treatment of Recurrent Depression in France

Nuijten, Mark; Hadjadjeba, Lionel; Evans, Christopher; … - In: PharmacoEconomics 14 (1998) 4, pp. 433-445

constructed to model the effectiveness, as measured by time without depression, and the costs of both treatments. The model … favoured fluvoxamine as it was associated with a longer period of time without depression when compared with TCAs (79% of the …

Persistent link: https://www.econbiz.de/10005404792

Reducing the Societal Burden of Depression: A Review of Economic Costs, Quality of Care and Effects of Treatment

Donohue, Julie M.; Pincus, Harold Alan - In: PharmacoEconomics 25 (2007) 1, pp. 7-24

Depression is a highly prevalent condition that results in substantial functional impairment. Advocates have attempted … in recent years to make the `business case' for investing in quality improvement efforts in depression care, particularly … in primary care settings. The business case suggests that the costs of depression treatment may be offset by gains in …

Persistent link: https://www.econbiz.de/10004990342

The Economic Impact of Neuropsychiatric Symptoms in Alzheimer's Disease: Can Drugs Ease the Burden?

Murman, Daniel L.; Colenda, Christopher C. - In: PharmacoEconomics 23 (2005) 3, pp. 227-242

The majority of patients with Alzheimer's disease (AD) will have clinically significant neuropsychiatric symptoms during the course of their disease. There is growing evidence that neuropsychiatric symptoms increase direct costs of care in patients with AD, especially the costs associated with...

Persistent link: https://www.econbiz.de/10005449320

The Economic Burden of Migraine to Society

Ferrari, Michel D. - In: PharmacoEconomics 13 (1998) 6, pp. 667-676

The financial burden of migraine on society comprises direct costs, associated with medical care, and indirect costs, caused by absence from work and reduced productivity. Recent studies have revealed that direct costs are generally relatively low in Europe, but are much higher in North America,...

Persistent link: https://www.econbiz.de/10005404782

Lower Respiratory Tract Infections: Impact on the Workplace

Birnbaum, Howard G.; Morley, Melissa; Leong, Stephanie; … - In: PharmacoEconomics 21 (2003) 10, pp. 749-759

Background: While there is some literature on the cost of specific respiratory infections, much of the existing research focuses only on direct medical treatment costs and does not take into consideration workplace burden due to disability and absenteeism. Objective: To evaluate the impact of...

Persistent link: https://www.econbiz.de/10005404783

Economic Models of Antiretroviral Therapy: Searching for the Optimal Strategy

Hellinger, Fred J. - In: PharmacoEconomics 24 (2006) 7, pp. 631-642

The diffusion of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in the US in 1996 and 1997 reduced the number of deaths attributable to HIV disease and changed the way we think about the illness. Today, HIV disease may be deemed a fairly expensive chronic condition...

Persistent link: https://www.econbiz.de/10005404811

Validation of Expert Opinion in Identifying Comorbidities Associated with Atopic Dermatitis/Eczema

Ellis, Charles N.; Drake, Lynn A.; Prendergast, Mary M.; … - In: PharmacoEconomics 21 (2003) 12, pp. 875-883

Background: The use of expert opinion is widespread in economic studies of healthcare utilisation; however, few studies have attempted to assess the validity of assumptions derived from such sources. Objective: To examine the use of such expert opinion in determining comorbidities associated...

Persistent link: https://www.econbiz.de/10005404820

Acute Pyelonephritis Among Adults: Cost of Illness and Considerations for the Economic Evaluation of Therapy

Brown, Patricia; Ki, Moran; Foxman, Betsy - In: PharmacoEconomics 23 (2005) 11, pp. 1123-1142

Urinary tract infection (UTI) is an infection anywhere in the urinary tract, most commonly due to bacteria. If infection involves the kidney, the UTI is termed acute pyelonephritis (APN). An estimated 10-30% of all patients with APN are hospitalised for treatment; in the US, the incidence of...

Persistent link: https://www.econbiz.de/10005404822

Dennison, Cheryl; Prasad, Manishi; Lloyd, Andrew; … - In: PharmacoEconomics 23 (2005) 5, pp. 461-476

Constipation is a prevalent condition that disproportionately affects women and older adults and leads to self-medication and/or medical consultation. It occurs as a result of functional idiopathic causes or secondarily as a result of a variety of factors including dietary and exercise patterns,...

Persistent link: https://www.econbiz.de/10005404833

Hepatitis C: Cost of Illness and Considerations for the Economic Evaluation of Antiviral Therapies

Wong, John B. - In: PharmacoEconomics 24 (2006) 7, pp. 661-672

Chronic hepatitis C virus (HCV) infection affects 170 million individuals worldwide. As it is detected incidentally through the evaluation of liver function tests or at the time of blood donor testing, it is usually clinically silent until the advanced stages of liver disease have occurred, when...

Persistent link: https://www.econbiz.de/10005404847